TY - JOUR
T1 - β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy
T2 - Are risks related to individual product safety profile?
AU - Smith, Derek M.
AU - Coop, Christopher A.
AU - Freeman, Theodore M.
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Purpose of reviewThe objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or β-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets.Recent findingsA literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, β-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or β-blockers. The adverse reaction rates seem similar between SLIT products.SummaryA risk-versus-benefit discussion should be communicated with the patient taking a β-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted.
AB - Purpose of reviewThe objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or β-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets.Recent findingsA literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, β-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or β-blockers. The adverse reaction rates seem similar between SLIT products.SummaryA risk-versus-benefit discussion should be communicated with the patient taking a β-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted.
KW - anaphylaxis
KW - angiotensin-converting enzyme inhibitor
KW - sublingual immunotherapy
KW - β-blocker
UR - http://www.scopus.com/inward/record.url?scp=85087320495&partnerID=8YFLogxK
U2 - 10.1097/ACI.0000000000000657
DO - 10.1097/ACI.0000000000000657
M3 - Review article
C2 - 32590508
AN - SCOPUS:85087320495
SN - 1473-6322
VL - 20
SP - 401
EP - 406
JO - Current opinion in allergy and clinical immunology
JF - Current opinion in allergy and clinical immunology
IS - 4
ER -